Here at dQ&A, we’ve been donating our time and resources to investigate how people with diabetes are faring during the COVID-19 pandemic. Since the beginning of March, we have heard regularly from nearly 5,000 people with diabetes about the many aspects of their lives that have been impacted.
One change has been the dramatic growth in telemedicine:
- Telemedicine has accounted for close to half of scheduled appointments for people with diabetes since early March.
- Overall, patients seem enthusiastic (54% report being “very satisfied”), but there were marked differences in satisfaction scores by appointment outcome, by whether video was used, by how blood glucose meter data were handled, and even by continuous glucose monitor (CGM) brand.
Insights like these left us wondering what post-lockdown diabetes care will look like, and specifically, what telemedicine’s role will be. COVID-19 has brought an unprecedented opportunity to understand what’s working (and not working) in telemedicine today, and what the industry can learn to provide better products/services as telemedicine inevitably plays a larger role going forward.
While we will continue to track the effects of COVID-19 on the diabetes community, we are launching a strategic study with patients, HCPs, and payers to more fully understand how telemedicine will shape diabetes care and what the implications are for industry.
If you’d like to learn more about this project, or have questions about our data, please fill out the form below or email us at firstname.lastname@example.org.
Sign up for our newsletter to receive the latest data and news from dQ&A.
About dQ&A – The Diabetes Research Company
dQ&A is a social enterprise that’s committed to making life better for people with diabetes. We harness patient voices to help develop better products, services and policies, answer key business questions and improve health outcomes for people with diabetes. For ten years, we have focused exclusively on understanding what life is like for those with diabetes. We are trusted by patients because of our independence and commitment to them. And we are endorsed by industry leaders because we deliver high quality answers quickly and efficiently, through the use of our proprietary community. Our team has decades of experience in quantitative and qualitative research and a deep knowledge of diabetes. Many of our lives have been touched by diabetes, so we have a personal stake in our work.